Abbott Laboratories (NYSE: ABT) — Perfil da empresa, notícias e dados financeiros
Abbott Laboratories is a global healthcare company offering pharmaceuticals, diagnostics, medical devices, and nutritional products.
Abbott Laboratories
Abbott Laboratories is a global healthcare company that discovers, develops, manufactures, and sells a broad range of health products and medical technologies. The company operates across four primary business segments: Medical Devices, Diagnostics, Established Pharmaceuticals, and Nutrition. Its product portfolio includes continuous glucose monitoring systems, cardiovascular devices, core laboratory diagnostic equipment, rapid testing kits, branded generic pharmaceuticals, pediatric infant formulas, and adult clinical nutrition supplements. Abbott serves healthcare providers, institutions, and consumers across more than 160 countries, operating research, manufacturing, and distribution facilities globally to support healthcare delivery across diverse therapeutic areas.
Resumo
Operações
Produtos e/ou serviços de Abbott Laboratories
- Medical Devices - Diabetes Care: Development and manufacture of continuous glucose monitoring systems, biowearable sensors, and digital health software that track glucose levels in real time for individuals managing diabetes and metabolic health without requiring routine fingersticks.
- Medical Devices - Cardiovascular and Neuromodulation: Production of structural heart devices, cardiac electrophysiology systems, vessel closure tools, heart failure monitors, and implantable neuromodulation therapies designed to manage chronic pain, movement disorders, coronary artery disease, and structural heart conditions.
- Diagnostic Systems and Tests: Supply of automated core laboratory testing systems, molecular diagnostic instruments, point-of-care analyzers, and rapid infectious disease test kits utilized by hospitals, blood banks, reference laboratories, and clinics worldwide for clinical decision-making.
- Established Pharmaceuticals: Manufacture and commercial distribution of branded generic medications and specialty pharmaceuticals covering gastroenterology, cardiology, women's health, respiratory conditions, and metabolic disorders, marketed primarily across emerging geographic regions.
- Pediatric Nutrition: Formulation and global distribution of science-based infant formulas, follow-on formulas, oral rehydration solutions, and specialized pediatric nutritional products tailored for infant development, allergy management, and specific pediatric clinical requirements.
- Adult Nutrition: Production and sale of targeted adult clinical nutrition products, oral meal replacements, and dietary supplements designed to assist recovery, support muscle preservation, manage blood glucose levels, and fulfill specialized daily nutritional requirements.
equipe executiva do Abbott Laboratories
- Robert B. FordExecutive Chairman & CEO
- Philip P. BoudreauCFO & Executive VP of Finance
- Daniel Gesua Sive SalvadoriExecutive VP and Group President of Established Pharmaceuticals & Nutritional Products
- Christopher J. ScogginsExecutive Vice President of Diabetes Care
- Lisa D. EarnhardtExecutive VP & Group President of Medical Devices
- Sabina EwingSenior VP of Business & Technology Services and Chief Information Officer
- Michael ComillaVice President of Investor Relations.
- Erica L. BattagliaVP and Chief Ethics & Compliance Officer
- Elizabeth C. CushmanExecutive VP, General Counsel & Secretary
- Melissa BrotzSenior Vice President of Global Marketing & External Affairs
Últimas notícias sobre a Abbott Laboratories
Abbott Q3 sales rise 14.5% to $13.01 billion amid planned Nutrition spinoff
United StatesAbbott wins FDA approval for CardioMEMS HF smartphone app updates
United StatesAbbott wins FDA approval for AFib catheter
United StatesAbbott delivers $12.6 billion second quarter sales
United StatesALZpath licenses pTau217 antibody to Abbott
United StatesAbbott reports Q1 revenue rises 3.7% to $11.16 billion
United States
Histórico de dividendos
Dividendos por ação pagos pela Abbott Laboratories, por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2026(até o momento) | — | — | — | $2.5200 |
| FY2025 | — | — | — | $2.3600 |
| FY2024 | — | — | — | $2.2000 |
| FY2023 | — | — | — | $2.0400 |
| FY2022 | — | — | — | $1.8800 |
Principais indicadores financeiros
Resultados divulgados pela Abbott Laboratories, em USD.
- Cap. de mercado
- 191,4 bi
- Receita (TTM)
- 48,2 bi
- P/L
- 41.2
- LPA (diluído, TTM)
- 2.7
- Dividend yield
- 2.3%
- Margem de lucro
- 9.8%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 44,3 bi | 8 bi | 6,5 bi | |
| 42 bi | 6,8 bi | 13,4 bi | |
| 40,1 bi | 6,4 bi | 5,7 bi | |
| 43,7 bi | 8,4 bi | 6,9 bi |